Trial · NCT02324608
Adverse events44
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 44
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Rash maculo-papular | Skin and subcutaneous tissue disorders | Treatment (Cetuximab) | 6 | 15 | 7 |
| other | Rash acneiform | Skin and subcutaneous tissue disorders | Treatment (Cetuximab) | 5 | 15 | 8 |
| other | Dry skin | Skin and subcutaneous tissue disorders | Treatment (Cetuximab) | 3 | 15 | 3 |
| other | Skin and subcutaneous tissue disorders - Other, specify | Skin and subcutaneous tissue disorders | Treatment (Cetuximab) | 1 | 15 | 1 |
| other | Hypomagnesemia | Metabolism and nutrition disorders | Treatment (Cetuximab) | 9 | 15 | 10 |
| other | Dehydration | Metabolism and nutrition disorders | Treatment (Cetuximab) | 2 | 15 | 2 |
| other | Hyperkalemia | Metabolism and nutrition disorders | Treatment (Cetuximab) | 1 | 15 | 1 |
| other | Anorexia | Metabolism and nutrition disorders | Treatment (Cetuximab) | 1 | 15 | 1 |
| other | Hypocalcemia | Metabolism and nutrition disorders | Treatment (Cetuximab) | 1 | 15 | 1 |
| other | Fatigue | General disorders | Treatment (Cetuximab) | 1 | 15 | 1 |
| other | Chills | Gastrointestinal disorders | Treatment (Cetuximab) | 1 | 15 | 1 |
| other | Pain | General disorders | Treatment (Cetuximab) | 1 | 15 | 1 |
| other | Fall | Injury, poisoning and procedural complications | Treatment (Cetuximab) | 2 | 15 | 2 |
| other | Bruising | Injury, poisoning and procedural complications | Treatment (Cetuximab) | 1 | 15 | 1 |
| other | Wound complication | Injury, poisoning and procedural complications | Treatment (Cetuximab) | 1 | 15 | 1 |
| other | Hypertension | Vascular disorders | Treatment (Cetuximab) | 3 | 15 | 6 |
| other | Hypotension | Vascular disorders | Treatment (Cetuximab) | 1 | 15 | 1 |
| other | Eye disorders - Other, specify | Eye disorders | Treatment (Cetuximab) | 2 | 15 | 2 |
| other | Dry eye | Eye disorders | Treatment (Cetuximab) | 1 | 15 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Treatment (Cetuximab) | 2 | 15 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02324608/events